审核状态: Project audit state: |
通过审核 Successful |
注册号: Registration number: |
ChiCTR-TRC-13003242 |
最近更新时间: Date of Last Refreshed on: |
2016/2/7 19:30:04 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
填写语言: |
中文和英文 |
Language: |
Chinese And English |
注册题目: |
鹿红颗粒防治冠心病心功能不全的多中心临床研究 |
Public title: |
Lu Hong Granule in management of Heart Failure in Coronary Artery Disease patients: A randomized multi-center study. |
注册题目简写: |
|
Public title acronym: |
LHKL-CAD-HF |
研究课题的正式科学名称: |
鹿红颗粒防治冠心病心功能不全的多中心临床研究 |
Scientific title: |
Integrative Medicine program optimization study in coronary artery disease with heart failure |
研究课题的正式科学名称简写: |
|
Scientific title acronym: |
|
研究课题代号(代码): Study subject ID: |
|
在其它机构的注册号: Secondary ID: |
申请注册联系人: |
王肖龙 |
研究负责人: |
王肖龙 |
Applicant: |
Wang Xiao-long |
Study leader: |
Wang Xiao-long |
申请注册联系人电话: Applicant telephone: |
+86 13501991450 |
研究负责人电话: Study leader's telephone: |
+86 13501991450 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
wxlqy0214@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wxlqy0214@163.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
上海市普安路185号 |
研究负责人通讯地址: |
上海市普安路185号 |
Applicant address: |
185 Pu'an Road, Shanghai |
Study leader's address: |
185 Pu'an Road, Shanghai |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
上海中医药大学附属曙光医院 |
||
Applicant's institution: |
Shuguang hospital affiliated to Shanghai university of Traditional Chinese Medicine |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
2013-259-28-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
批准本研究的伦理委员会名称: |
上海中医药大学附属曙光医院伦理委员会 |
||
Name of the ethic committee: |
Ethics Committee of Shuguang hospital affiliated to Shanghai university of Traditional Chinese Medicine |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2013-05-07 | ||
国家FDA批准文号: Approved No. of SFDA: |
国家FDA批准附件: Approved file of SFDA: |
|
|
国家FDA批准日期: Date of approved by SFDA: |
研究实施负责(组长)单位: |
上海中医药大学附属曙光医院 |
Primary sponsor: |
Shuguang hospital affiliated to Shanghai university of Traditional Chinese Medicine |
研究实施负责(组长)单位地址: |
上海市普安路185号 |
Primary sponsor's address: |
185 Pu'an Road, Luwan District, Shanghai, China |
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
经费或物资来源: |
上海市卫生局 |
Source(s) of funding: |
Shanghai Municipal Health Bureau |
研究疾病: |
冠心病合并心功能不全 |
Target disease: |
Coronary artery disease with heart failure |
研究疾病代码: |
|
Target disease code: |
|
研究类型: |
干预性研究 |
Study type: |
Interventional study |
研究所处阶段: |
I期临床试验 |
Study phase: |
1 |
研究目的: |
评价鹿红颗粒治疗冠心病合并心功能不全的有效性和安全性 |
Objectives of Study: |
To evaluate the clinical efficiency and safety on Lu Hong Granule treating coronary artery disease patients with heart failure |
研究设计: |
随机平行对照 |
Study design: |
Parallel |
纳入标准: |
18-85岁,性别不限;符合冠心病诊断标准;符合左心功能不全诊断标准;鹿红颗粒组符合中医阳虚血瘀证判定标准;符合NYHA分级II-IV级 |
Inclusion criteria |
Aged from 18-85 with no sex limitation; diagnosis in coronary artery disease with left ventricular dysfunction; Lu Hong Granule treatment group should with TCM diagosis yang deficient and blood stasis; in class II-IV heart failure diagosis by New York Heart Association. |
排除标准: |
持续严重心绞痛(CCS Ⅳ级);试验期间准备行CABG或PCI者;肾功能不全(Cr>1.5倍正常参考值上限);严重肝病患者或肝功能不全(ALT、AST或TBIL>2倍正常参考值上限);任何其它严重的疾病或状况如:恶性肿瘤;正在参加另一个临床研究;孕妇或准备怀孕的妇女;研究者判断认为不适合参加本研究的患者 |
Exclusion criteria: |
persistant severe angina (CCS Class IV); undertaking CABG or PCI surgery during the trial; kidney failure with SCr>1.5*ULN; severe liver disease or abnormal in liver biomarks(ALT, AST or TBil>2* ULN); any other severe disease or situation like malignant tumor; undertaking another clinical trial; pregnant woman or preparing to pregnant; researchers think not being suitable to participate in this study. |
研究实施时间: Study execute time: |
从From2013-05-01至To 2014-09-21 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|
采集人体标本:
Collecting sample(s)
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Pending |
年龄范围: Participant age: |
|
||||||
性别: |
男女均可 |
Gender: |
Both |
||||||
随机方法(请说明由何人用什么方法产生随机序列): |
设专人采用随机数字表随机 |
||||||||
Randomization Procedure (please state who generates the random number sequence and by what method): |
Designated persons using a random number table random |
||||||||
UTN(全球唯一识别码): |
盲法: |
|
Blinding: |
|
试验完成后的统计结果: |
|
Calculated Results ater
|
|
研究负责(组长)单位: |
|
Organizer institution (leader institution): |
|
资料收集汇总单位: |
|
Data collection Institution: |
|
资料管理单位: |
|
Data management Institution: |
|
资料分析单位: |
|
Data analysis Institution: |
|